Clinical factors predictive for histological aggressiveness of basal cell carcinoma: A prospective study of 2274 cases.


Journal

Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 05 05 2019
revised: 07 09 2019
accepted: 08 10 2019
pubmed: 14 12 2019
medline: 16 10 2021
entrez: 14 12 2019
Statut: ppublish

Résumé

Since surgery is the first-line treatment for basal cell carcinomas (BCC), the histological aggressiveness of the disease must be clinically predicted in order to apply optimal safety margins that ensure a high rate of complete resection while minimising the risk of recurrence. To evaluate clinical predictive factors of histological aggressiveness of BCC, we conducted a national prospective multi-centre study. All consecutive patients presenting for BCC surgery were included, and standardised clinical data collected, and slides were submitted for review. Trabecular, micronodular and morpheaform BCCs were classified as aggressive. Of the 2710 cases included, 2274 were histologically confirmed. Clinical subtyping was correct in 49.9% of superficial BCCs, 86.2% of nodular BCCs and only 22% of aggressive BCCs. By multivariate analysis, aggressive BCCs were more frequently ulcerated (45%), indurated (70%), showed adherence (8.6%), and were associated with high-risk anatomical zones (50.3%, P<0.0001). These predictive clinical features may be helpful for decision making.

Identifiants

pubmed: 31831218
pii: S0151-9638(19)31014-2
doi: 10.1016/j.annder.2019.10.028
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-27

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

J-M Amici (JM)

Department of Dermatology, Oncodermatology and Interventional Dermatology, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.

L Dousset (L)

Department of Dermatology, Oncodermatology and Interventional Dermatology, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.

M Battistella (M)

Pathology Laboratory, Saint-Louis Hospital, Public Assistance-Paris Hospitals (AP-HP), Paris, France.

B Vergier (B)

Pathology Laboratory, Bordeaux University Hospital, Bordeaux, France; Inserm Unit U1053, Bordeaux Research in Translational Oncology, Bordeaux University, Bordeaux, France.

J-Y Bailly (JY)

Private dermatology practice, Toulouse, France.

O Cogrel (O)

Department of Dermatology, Oncodermatology and Interventional Dermatology, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.

L Gusdorf (L)

Dermatopathology Laboratory, Dermatology Clinic, Strasbourg University Hospital, Strasbourg, France.

C Alfaro (C)

Department of Dermatology, Oncodermatology and Interventional Dermatology, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France.

K Ezzedine (K)

EA1379 EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques-Dermatological Epidemiology and Therapeutic Evaluation), Dermatology Department, Paris-Est University, Henri Mondor Hospital, Créteil, AP-HP, Créteil, France.

B Cribier (B)

Dermatopathology Laboratory, Dermatology Clinic, Strasbourg University Hospital, Strasbourg, France.

M Beylot-Barry (M)

Department of Dermatology, Oncodermatology and Interventional Dermatology, Bordeaux University Hospital, Saint-André Hospital, 1, rue Jean-Burguet, 33075 Bordeaux cedex, France; Inserm Unit U1053, Bordeaux Research in Translational Oncology, Bordeaux University, Bordeaux, France. Electronic address: marie.beylot-barry@chu-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH